| Description | Vinaxanthone (SM-345431) is a small molecule compound derived from Penicillium chrysogenum that is a selective and potent semaphorin3A, phospholipase C (PLC), and FabI inhibitor, inhibiting semaphorin3A and FabI.Vinaxanthone exhibits antimicrobial activity, blocking intracellular fatty acid synthesis and inhibiting the growth of Staphylococcus aureus. |
| In vitro | Vinaxanthone exhibits selective inhibitory activity against phospholipase C (PLC) in rat brain, mouse colon 26 adenocarcinoma, and mouse fibroblast NIH3T3 cells, with IC50 values of 5.4, 9.3, and 44 μM, respectively.At a concentration of 0.1 mg/mL for 24 hours, Vinaxanthone enhances peripheral nerve regeneration and induces limited neovascularization in the cornea[1].At a concentration of 0.5 μM for 20 minutes, Vinaxanthone may protect against Doxorubicin-induced apoptosis in foot cells[3].In the range of 0.1-1 μM for 24 hours, Vinaxanthone improves the changes in renal tubular cell characteristics induced by TGF-β1[2]. |
| In vivo | Vinaxanthone (SM-345431), administered by subconjunctival injection at a concentration of 0.1 mg/mL every two days for 3 weeks, accelerates peripheral nerve regeneration and functional recovery in a mouse corneal transplantation model[1].Vinaxanthone (SEMA3A-I), given by intraperitoneal injection at a dose of 20 µg, protects against podocyte injury induced by Adriamycin in a mouse model through an anti-apoptotic mechanism[3]. |
| Target activity | PA:9.3 μM (mouse colon 26 adenocarcinoma), PA:44 μM (NIH3T3 cell), PA:5.4 μM (Rat brain) |
| Synonyms | SM-345431 |
| molecular weight | 576.42 |
| Molecular formula | C28H16O14 |
| CAS | 133293-89-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 80 mg/mL (138.79 mM), Sonication is recommended. |
| References | 1. Omoto M,et al. The semaphorin 3A inhibitor SM-345431 accelerates peripheral nerve regeneration and sensitivity in a murine corneal transplantation model. PLoS One. 2012;7(11):e47716. 2. Sang Y, et al. Semaporin3A inhibitor ameliorates renal fibrosis through the regulation of JNK signaling. Am J Physiol Renal Physiol. 2021 Dec 1;321(6):F740-F756. 3. Sang Y, et al. Semaphorin3A-Inhibitor Ameliorates Doxorubicin-Induced Podocyte Injury. Int J Mol Sci. 2020 Jun 8;21(11):4099. |